Clinical trial
FLOX in Combination With Cetuximab in First-line Treatment of Colorectal Cancer
NCT00145314 · The Nordic Colorectal Cancer Biomodulation Group, Other · Completed
Key facts
| NCT number | NCT00145314 |
|---|---|
| Title | FLOX in Combination With Cetuximab in First-line Treatment of Colorectal Cancer |
| Official title | 5-Fluorouracil/Folinate/Oxaliplatin (Eloxatin) (FLOX Regimen), Given Continuously or Intermittently, in Combination With Cetuximab (Erbitux), in First-line Treatment of Metastatic Colorectal Cancer. A Phase III Multicenter Trial. |
| Lead sponsor | The Nordic Colorectal Cancer Biomodulation Group, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Metastatic Colorectal Cancer |
| Intervention type | Drug |
| Interventions | FLOX (5-fluorouracil/folinic acid/oxaliplatin), FLOX (5-fluorouracil/folinic acid/oxaliplatin) and Cetuximab, FLOX (5-fluorouracil and folinic acid and oxaliplatin) intermittently and maintenance cetuximab |
| Enrollment | 571 |
| Start date | May 1, 2005 |
| Primary completion | May 1, 2009 |
| Completion | Aug 1, 2010 |
| First posted | Sep 5, 2005 |
| Last update posted | Jan 14, 2011 |
| Countries | Norway |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: